New arthritis drug shows promise in early safety trial
NCT ID NCT03574545
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This early-stage study tested two versions of the drug ianalumab in 48 adults with active rheumatoid arthritis. The goal was to see if both forms are safe and work similarly in the body. Participants received multiple injections, and researchers monitored side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Amman, 11941, Jordan
Conditions
Explore the condition pages connected to this study.